Analysts' Actions: CBST EOG LRN MRK PFE

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Abercrombie & Fitch ( ANF) was downgraded to hold at TheStreet Ratings.

Cubist ( CBST) was upgraded at Mizuho to buy from neutral. $77 price target. Acquisitions should help drive near-term growth, Mizuho said.

C&J Energy ( CJES) was downgraded at Cowen to market perform from outperform. $22.30 price target. Fracturing services market continues to suffer from chronic oversupply, Cowen said.

Ellington Financial ( EFC) was upgraded to hold at TheStreet Ratings.

EOG Resources ( EOG) was upgraded at Credit Suisse to outperform from neutral. $175 price target. Estimates were also increased, given higher oil production forecasts, Credit Suisse said.

Iberiabank ( IBKC) was downgraded at Oppenheimer to perform from outperform. Company is seeing pressure in mortgage banking, Oppenheimer said.

K12 ( LRN) was downgraded at Robert Baird to neutral from outperform. $25 price target. Company slashed its guidance, Baird said.

K12 was downgraded at BMO Capital to market perform from outperform. $22 price target. Company is seeing lower enrollment growth, BMO Capital said.

Masco ( MAS) was upgraded at J.P. Morgan to overweight from neutral. $21 price target. Valuation is reasonable against unaggressive 2015 estimates, J.P. Morgan said.

Merck ( MRK) was initiated with a neutral rating at Credit Suisse. $49 price target. Core franchises are facing growth challenges, Credit Suisse said.

Owens Corning ( OC) was upgraded at J.P. Morgan to overweight from neutral. $45 price target. More constructive view on repair/remodel focused building product names, J.P. Morgan said.

Pfizer ( PFE) was initiated with an outperform rating at Credit Suisse. $34 price target. Restructuring story will likely continue to evolve, Credit Suisse said.

Patterson-UTI ( PTEN) was downgraded at Cowen to perform from outperform. $24 price target. Pressure pumping prices will likely show no improvement, Cowen said.

Viropharma ( VPHM) was downgraded at Mizuho to neutral from buy. Valuation call, based on a $39 price target, Mizuho said.

Stock Comments / EPS Changes

Hain Celestial ( HAIN) estimates were cut at Jefferies through 2013. Guidance below consensus at analyst day, Jefferies said. Buy rating and $91 price target.

If you liked this article you might like

Cubist Pharmaceuticals (CBST) Hits New Lifetime High

Trade-Ideas: Cubist Pharmaceuticals (CBST) Is Today's New Lifetime High Stock

Orphan Drug Company NPS Pharmaceuticals May Find Few Buyers

Jim Cramer on the Markets: Some Stocks You Just Can't Ignore

Cubist Pharmaceuticals (CBST): Today's Pre-Market Leader Stock